Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.

Biochimie - 1 Nov 2017

Mihailidou Chrysovalantou, Karamouzis Michalis V, Schizas Dimitrios, Papavassiliou Athanasios G

Abstract excerpt

Gastric cancer (GC) is a threatening malignancy characterized by heterogeneity. Current therapies use DNA damaging agents, for example, chemotherapeutic agents and ionizing radiation (IR). However, a significant portion of GC patients develops therapeutic resistance to DNA damage response (DDR) - inducing agents. An important mechanism is the stimulation of the c-MET RTK, which is a tyrosine kinase receptor and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Breaks, Double-Stranded
Share to HGF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MET gene

Share to Molecular Targeted Therapy

Share to Mutation

Share to Proto-Oncogene Proteins c-met

Share to Stomach Neoplasms

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 28890386
DOI: 10.1016/j.biochi.2017.09.001

Genes

BRCA1
BRCA2
HGF
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.PMID 28890386Read ↗

DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive ReviewSemantic proximity Read ↗

ATR-CHK1 Axis Inhibitors in Gastric Cancer TreatmentSemantic proximity Read ↗

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical PerspectivesSemantic proximity Read ↗

Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal CancerSemantic proximity Read ↗

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read ↗

Advancements and Obstacles of PARP Inhibitors in Gastric CancerSemantic proximity Read ↗

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal CancerSemantic proximity Read ↗

Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.Semantic proximity Read ↗

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical AspectsSemantic proximity Read ↗

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.Semantic proximity Read ↗

Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy ResponseSemantic proximity Read ↗

Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stressSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.